Louis Bernard1, Cédric Arvieux1, Benoit Brunschweiler1, Sophie Touchais1, Séverine Ansart1, Jean-Pierre Bru1, Eric Oziol1, Cyril Boeri1, Guillaume Gras1, Jérôme Druon1, Philippe Rosset1, Eric Senneville1, Houcine Bentayeb1, Damien Bouhour1, Gwenaël Le Moal1, Jocelyn Michon1, Hugues Aumaître1, Emmanuel Forestier1, Jean-Michel Laffosse1, Thierry Begué1, Catherine Chirouze1, Fréderic-Antoine Dauchy1, Edouard Devaud1, Benoît Martha1, Denis Burgot1, David Boutoille1, Eric Stindel1, Aurélien Dinh1, Pascale Bemer1, Bruno Giraudeau1, Bertrand Issartel1, Agnès Caille1. 1. From the Division of Infectious Diseases (L.B., G.G.), Orthopedic Unit (J.D., P.R.), and INSERM Centre d'Investigation Clinique 1415 (B.G., A.C.), University Hospital, and University of Tours and University of Nantes, INSERM, SPHERE (Methods in Patient-Centered Outcomes and Health Research) Unité 1246 (B.G., A.C.), Tours, the Division of Infectious Diseases, University Hospital, Rennes (C.A.), the Orthopedic Unit, University Hospital, Amiens (B.B.), the Orthopedic Unit (S.T.), the Division of Infectious Diseases (D. Boutoille), and the Department of Bacteriology (P.B.), University Hospital, Nantes, the Division of Infectious Diseases (S.A.) and Orthopedic Unit (E. Stindel), University Hospital, Brest, the Division of Infectious Diseases, Regional Hospital, Annecy (J.-P.B.), the Division of Infectious Diseases, Regional Hospital, Beziers (E.O., H.A.), the Orthopedic Unit, University Hospital, Strasbourg (C.B.), the Division of Infectious Diseases, University Hospital, Tourcoing (E. Senneville), the Division of Infectious Diseases, Regional Hospital, Saint Quentin (H.B.), the Division of Infectious Diseases, General Hospital, Bourg en Bresse (D. Bouhour), the Division of Infectious Diseases, University Hospital, Poitiers (G.L.M.), the Division of Infectious Diseases, University Hospital, Caen (J.M.), the Division of Infectious Diseases, Regional Hospital, Chambery (E.F.), the Orthopedic Unit, University Hospital, Toulouse (J.M.L.), the Orthopedic Unit, University Hospital, Clamart (T.B.), the Division of Infectious Diseases, University Hospital, Besançon (C.C.), the Division of Infectious Diseases, University Hospital, Bordeaux (F.-A.D.), the Division of Internal Medicine, Pointoise Hospital, Pointoise (E.D.), the Division of Infectious Diseases, Regional Hospital, Chalon (B.M.), the Orthopedic Unit, Blois Polyclinic, La Chaussée-Saint-Victor (D. Burgot), the Mobile Unit of the Infectious Referents, University Hospital, Garches (A.D.), and the Mobile Unit of the Infectious Referents, Villeurbanne (B.I.) - all in France.
Abstract
BACKGROUND: The management of prosthetic joint infection usually consists of a combination of surgery and antimicrobial therapy. The appropriate duration of antimicrobial therapy for this indication remains unclear. METHODS: We performed an open-label, randomized, controlled, noninferiority trial to compare 6 weeks with 12 weeks of antibiotic therapy in patients with microbiologically confirmed prosthetic joint infection that had been managed with an appropriate surgical procedure. The primary outcome was persistent infection (defined as the persistence or recurrence of infection with the initial causative bacteria, with an antibiotic susceptibility pattern that was phenotypically indistinguishable from that at enrollment) within 2 years after the completion of antibiotic therapy. Noninferiority of 6 weeks of therapy to 12 weeks of therapy would be shown if the upper boundary of the 95% confidence interval for the absolute between-group difference (the value in the 6-week group minus the value in the 12-week group) in the percentage of patients with persistent infection within 2 years was not greater than 10 percentage points. RESULTS: A total of 410 patients from 28 French centers were randomly assigned to receive antibiotic therapy for 6 weeks (205 patients) or for 12 weeks (205 patients). Six patients who withdrew consent were not included in the analysis. In the main analysis, 20 patients who died during follow-up were excluded, and missing outcomes for 6 patients who were lost to follow-up were considered to be persistent infection. Persistent infection occurred in 35 of 193 patients (18.1%) in the 6-week group and in 18 of 191 patients (9.4%) in the 12-week group (risk difference, 8.7 percentage points; 95% confidence interval, 1.8 to 15.6); thus, noninferiority was not shown. Noninferiority was also not shown in the per-protocol and sensitivity analyses. We found no evidence of between-group differences in the percentage of patients with treatment failure due to a new infection, probable treatment failure, or serious adverse events. CONCLUSIONS: Among patients with microbiologically confirmed prosthetic joint infections that were managed with standard surgical procedures, antibiotic therapy for 6 weeks was not shown to be noninferior to antibiotic therapy for 12 weeks and resulted in a higher percentage of patients with unfavorable outcomes. (Funded by Programme Hospitalier de Recherche Clinique, French Ministry of Health; DATIPO ClinicalTrials.gov number, NCT01816009.).
BACKGROUND: The management of prosthetic joint infection usually consists of a combination of surgery and antimicrobial therapy. The appropriate duration of antimicrobial therapy for this indication remains unclear. METHODS: We performed an open-label, randomized, controlled, noninferiority trial to compare 6 weeks with 12 weeks of antibiotic therapy in patients with microbiologically confirmed prosthetic joint infection that had been managed with an appropriate surgical procedure. The primary outcome was persistent infection (defined as the persistence or recurrence of infection with the initial causative bacteria, with an antibiotic susceptibility pattern that was phenotypically indistinguishable from that at enrollment) within 2 years after the completion of antibiotic therapy. Noninferiority of 6 weeks of therapy to 12 weeks of therapy would be shown if the upper boundary of the 95% confidence interval for the absolute between-group difference (the value in the 6-week group minus the value in the 12-week group) in the percentage of patients with persistent infection within 2 years was not greater than 10 percentage points. RESULTS: A total of 410 patients from 28 French centers were randomly assigned to receive antibiotic therapy for 6 weeks (205 patients) or for 12 weeks (205 patients). Six patients who withdrew consent were not included in the analysis. In the main analysis, 20 patients who died during follow-up were excluded, and missing outcomes for 6 patients who were lost to follow-up were considered to be persistent infection. Persistent infection occurred in 35 of 193 patients (18.1%) in the 6-week group and in 18 of 191 patients (9.4%) in the 12-week group (risk difference, 8.7 percentage points; 95% confidence interval, 1.8 to 15.6); thus, noninferiority was not shown. Noninferiority was also not shown in the per-protocol and sensitivity analyses. We found no evidence of between-group differences in the percentage of patients with treatment failure due to a new infection, probable treatment failure, or serious adverse events. CONCLUSIONS: Among patients with microbiologically confirmed prosthetic joint infections that were managed with standard surgical procedures, antibiotic therapy for 6 weeks was not shown to be noninferior to antibiotic therapy for 12 weeks and resulted in a higher percentage of patients with unfavorable outcomes. (Funded by Programme Hospitalier de Recherche Clinique, French Ministry of Health; DATIPO ClinicalTrials.gov number, NCT01816009.).
Authors: Oren Gordon; Donald E Lee; Bessie Liu; Brooke Langevin; Alvaro A Ordonez; Dustin A Dikeman; Babar Shafiq; John M Thompson; Paul D Sponseller; Kelly Flavahan; Martin A Lodge; Steven P Rowe; Robert F Dannals; Camilo A Ruiz-Bedoya; Timothy D Read; Charles A Peloquin; Nathan K Archer; Lloyd S Miller; Kimberly M Davis; Jogarao V S Gobburu; Sanjay K Jain Journal: Sci Transl Med Date: 2021-12-01 Impact factor: 17.956
Authors: Noah Wald-Dickler; Paul D Holtom; Matthew C Phillips; Robert M Centor; Rachael A Lee; Rachel Baden; Brad Spellberg Journal: Am J Med Date: 2021-10-27 Impact factor: 4.965
Authors: Simon Hackl; Katharina Trenkwalder; Matthias Militz; Peter Augat; Fabian M Stuby; Christian von Rüden Journal: Unfallchirurgie (Heidelb) Date: 2022-06-24
Authors: T Fintan Moriarty; Willem-Jan Metsemakers; Mario Morgenstern; Marloes I Hofstee; Alejandro Vallejo Diaz; James E Cassat; Britt Wildemann; Melissa Depypere; Edward M Schwarz; R Geoff Richards Journal: Nat Rev Dis Primers Date: 2022-10-20 Impact factor: 65.038
Authors: W P Zijlstra; J J W Ploegmakers; G A Kampinga; M L Toren-Wielema; H B Ettema; B A S Knobben; P C Jutte; M Wouthuyzen-Bakker Journal: Arthroplasty Date: 2022-04-11
Authors: Brad Spellberg; Gloria Aggrey; Meghan B Brennan; Brent Footer; Graeme Forrest; Fergus Hamilton; Emi Minejima; Jessica Moore; Jaimo Ahn; Michael Angarone; Robert M Centor; Kartikeya Cherabuddi; Jennifer Curran; Kusha Davar; Joshua Davis; Mei Qin Dong; Bassam Ghanem; Doug Hutcheon; Philipp Jent; Minji Kang; Rachael Lee; Emily G McDonald; Andrew M Morris; Rebecca Reece; Ilan S Schwartz; Miranda So; Steven Tong; Christopher Tucker; Noah Wald-Dickler; Erica J Weinstein; Riley Williams; Christina Yen; Shiwei Zhou; Todd C Lee Journal: JAMA Netw Open Date: 2022-05-02
Authors: Uta S Koepf; Sebastian Scheidt; Gunnar T R Hischebeth; Christian P Strassburg; Dieter C Wirtz; Thomas M Randau; Philipp Lutz Journal: BMC Infect Dis Date: 2022-04-19 Impact factor: 3.667
Authors: M M Pettigrew; J Kwon; J F Gent; Y Kong; M Wade; D J Williams; C B Creech; S Evans; Q Pan; E B Walter; J M Martin; J S Gerber; J G Newland; M E Hofto; M A Staat; V G Fowler; H F Chambers; W C Huskins Journal: mBio Date: 2022-03-24 Impact factor: 7.786